in vivo fly RNAi

Micropublication relevant to TRiP fly stocks

April 9, 2019

Users of TRiP RNAi and sgRNA fly stocks take note: the Weake lab at Purdue University brought to our attention that some TRiP fly stocks carry a mutant allele of seveneless. Jonathan Zirin worked with Spencer Escobedo and Vikki Weake, as well as with folks at the Bloomington Drosophila Stock Center, to quickly identify the source, sequence the mutant allele, and pubilsh a micropublication so we can get the details to the community. Bottom line, as stated in the micropublication, "The presence of the sev[21]  mutation will not generally affect the use of these stocks, as the X...

Read more about Micropublication relevant to TRiP fly stocks
2018 Apr 13

DRSC & TRiP Workshop at ADRC

1:45pm to 3:45pm


Philadelphia, PA, USA
The DRSC & TRiP will be hosting a workshop at the Annual Drosophila Research Conference in Philadelphia, PA. The workshop is scheduled for Friday, April 13th from 1:45 to 3:45 PM. Come hear from DRSC & TRiP leaders Norbert Perrimon, Jonathan Zirin (organizer), Claire Yanhui Hu, and Stephanie Mohr. At the workshop, you will learn about new opportunities for community nomination and experiments using CRISPR knockout and activation, as well as learn what's new and popular among our online software and database tools. There will be something for everyone -- we will provide information... Read more about DRSC & TRiP Workshop at ADRC

New stocks added to the TRiP in vivo RNAi library

January 6, 2017

The TRiP has updated and curated our list of in vivo RNAi reagents for gene knockdown in fruitflies. To date, we have produced over 13,000 stocks for the benefit of the scientific community.

Visit the in vivo RNAi fly stocks and vectors page to download an excel file with the full list of fly stocks now available for order from the Bloomington Drosophila Stock Center (BDSC) and the...

Read more about New stocks added to the TRiP in vivo RNAi library
Benjamin E Housden, Matthias Muhar, Matthew Gemberling, Charles A Gersbach, Didier YR Stainier, Geraldine Seydoux, Stephanie E Mohr, Johannes Zuber, and Norbert Perrimon. 10/31/2016. “Loss-of-function genetic tools for animal models: cross-species and cross-platform differences.” Nat Rev Genet. Publisher's VersionAbstract

Our understanding of the genetic mechanisms that underlie biological processes has relied extensively on loss-of-function (LOF) analyses. LOF methods target DNA, RNA or protein to reduce or to ablate gene function. By analysing the phenotypes that are caused by these perturbations the wild-type function of genes can be elucidated. Although all LOF methods reduce gene activity, the choice of approach (for example, mutagenesis, CRISPR-based gene editing, RNA interference, morpholinos or pharmacological inhibition) can have a major effect on phenotypic outcomes. Interpretation of the LOF phenotype must take into account the biological process that is targeted by each method. The practicality and efficiency of LOF methods also vary considerably between model systems. We describe parameters for choosing the optimal combination of method and system, and for interpreting phenotypes within the constraints of each method.

Screenshot of the Online Tools Overview page

Is it a hit? On mining our data sets.

July 22, 2016

The DRSC/TRiP-FGR's FlyRNAi database stores results from the many cell-based screens done since 2003 using DRSC Drosophila RNAi libraries. It also stores information about knockdown and phenotypes resulting from specific combinations of in vivo RNAi fly stocks (including our TRiP stocks and also VDRC and NIG-Japan stocks). The in vivo data includes directly deposited data and results curated by FlyBase from the literature.

Even if you are not interested to do a fly RNAi screen, these data might help you. For...

Read more about Is it a hit? On mining our data sets.
Publication describes TRiP resources

Publication describes TRiP resources

July 8, 2016

Liz Perkins and colleagues have published a paper describing the Drosophila Transgenic RNAi Project (TRiP) at Harvard Medical School. The article, published in the November 1, 2015 issue of Geneticsdetails the TRiP production pipeline, reagents generated, state of the collection, and validation efforts.

This is a great introduction to the many in vivo RNAi resources the DRSC/TRiP-FGR provides to the scientific community.


Read more about Publication describes TRiP resources
2016 Sep 23

Boston Area Drosophila Meeting

1:00pm to 4:30pm


University of Massachusetts Boston

The DRSC-Functional Genomics Resources (formerly DRSC & TRiP) will be participating in the Boston Area Drosophila Meeting, which was organized by Alexey Verakas of UMass Boston and Jim Walker of Harvard Medical School. Hear about what's new in technologies and online tools at this regional meeting of experts in Drosophila research.

Search results for the term oogenesis at the Drosophila protocols portal

Beta-testing a "Drosophila Protocols Portal"

June 16, 2016

The DRSC-FGR has developed a beta version of a database and online search for protocols, the Drosophila Protocols Portal, relevant to Drosophila research. The goal is to provide a central portal for protocols distributed across the web. We collected protocols from protocol databases, lab websites, YouTube, Drosophila Information Service (DIS), and relevant journals. You can view the results by topic or search for specific terms.

Longer-term goals...

Read more about Beta-testing a "Drosophila Protocols Portal"
2016 Sep 28

Functional genomics techniques in Drosophila and their potential application in non-model insects

11:45am to 12:00pm


Orlando, FL

DRSC-FGR Director S. Mohr will be presenting in the symposium Insect Genetic Technologies: State of the Art and Promise for the Future at the International Congress of Entomology (ICE 2016). Come hear what is possible in Drosophila that might be applied to other insect species. Wednesday, September 28, 2016 at 11:45 am (symposium from 9:30 - 12:30).

Ian T Flockhart, Matthew Booker, Yanhui Hu, Benjamin McElvany, Quentin Gilly, Bernard Mathey-Prevot, Norbert Perrimon, and Stephanie E Mohr. 2012. “ database of the Drosophila RNAi screening center: 2012 update.” Nucleic Acids Res, 40, Database issue, Pp. D715-9.Abstract

FlyRNAi (, the database and website of the Drosophila RNAi Screening Center (DRSC) at Harvard Medical School, serves a dual role, tracking both production of reagents for RNA interference (RNAi) screening in Drosophila cells and RNAi screen results. The database and website is used as a platform for community availability of protocols, tools, and other resources useful to researchers planning, conducting, analyzing or interpreting the results of Drosophila RNAi screens. Based on our own experience and user feedback, we have made several changes. Specifically, we have restructured the database to accommodate new types of reagents; added information about new RNAi libraries and other reagents; updated the user interface and website; and added new tools of use to the Drosophila community and others. Overall, the result is a more useful, flexible and comprehensive website and database.

Felix Muerdter, Paloma M Guzzardo, Jesse Gillis, Yicheng Luo, Yang Yu, Caifu Chen, Richard Fekete, and Gregory J Hannon. 2013. “A genome-wide RNAi screen draws a genetic framework for transposon control and primary piRNA biogenesis in Drosophila.” Mol Cell, 50, 5, Pp. 736-48.Abstract

A large fraction of our genome consists of mobile genetic elements. Governing transposons in germ cells is critically important, and failure to do so compromises genome integrity, leading to sterility. In animals, the piRNA pathway is the key to transposon constraint, yet the precise molecular details of how piRNAs are formed and how the pathway represses mobile elements remain poorly understood. In an effort to identify general requirements for transposon control and components of the piRNA pathway, we carried out a genome-wide RNAi screen in Drosophila ovarian somatic sheet cells. We identified and validated 87 genes necessary for transposon silencing. Among these were several piRNA biogenesis factors. We also found CG3893 (asterix) to be essential for transposon silencing, most likely by contributing to the effector step of transcriptional repression. Asterix loss leads to decreases in H3K9me3 marks on certain transposons but has no effect on piRNA levels.

Joost Schulte, Katharine J Sepp, Chaohong Wu, Pengyu Hong, and Troy J Littleton. 2011. “High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model.” PLoS One, 6, 8, Pp. e23841.Abstract

To identify Huntington's Disease therapeutics, we conducted high-content small molecule and RNAi suppressor screens using a Drosophila primary neural culture Huntingtin model. Drosophila primary neurons offer a sensitive readout for neurotoxicty, as their neurites develop dysmorphic features in the presence of mutant polyglutamine-expanded Huntingtin compared to nonpathogenic Huntingtin. By tracking the subcellular distribution of mRFP-tagged pathogenic Huntingtin and assaying neurite branch morphology via live-imaging, we identified suppressors that could reduce Huntingtin aggregation and/or prevent the formation of dystrophic neurites. The custom algorithms we used to quantify neurite morphologies in complex cultures provide a useful tool for future high-content screening approaches focused on neurodegenerative disease models. Compounds previously found to be effective aggregation inhibitors in mammalian systems were also effective in Drosophila primary cultures, suggesting translational capacity between these models. However, we did not observe a direct correlation between the ability of a compound or gene knockdown to suppress aggregate formation and its ability to rescue dysmorphic neurites. Only a subset of aggregation inhibitors could revert dysmorphic cellular profiles. We identified lkb1, an upstream kinase in the mTOR/Insulin pathway, and four novel drugs, Camptothecin, OH-Camptothecin, 18β-Glycyrrhetinic acid, and Carbenoxolone, that were strong suppressors of mutant Huntingtin-induced neurotoxicity. Huntingtin neurotoxicity suppressors identified through our screen also restored viability in an in vivo Drosophila Huntington's Disease model, making them attractive candidates for further therapeutic evaluation.